The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

Klaus P. Machold*, Robert Landewe, Josef S. Smolen, Tanja A. Stamm, Desiree M. van der Heijde, Kirsten N. Verpoort, Kerstin Brickmann, Janitzia Vazquez-Mellado, Dimitri E. Karateev, Ferdinand C. Breedveld, Paul Emery, Thomas W. J. Huizinga

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

70 Citations (Web of Science)


Background Glucocorticoids (GCs) are often used as early arthritis treatment and it has been suggested that they induce remission or at least delay the development of rheumatoid arthritis (RA) and the need to start disease-modifying antirheumatic drugs (DMARDs). Objective To test the effect of GCs on patients with very early arthritis (symptom duration of
Original languageEnglish
Pages (from-to)495-502
JournalAnnals of the Rheumatic Diseases
Issue number3
Publication statusPublished - Mar 2010

Cite this